Beta Drugs Limited has informed the Exchange about Beta Drugs Expands International Market Access with Key Regulatory Milestones in Azerbaijan and Philippines.
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Beta Drugs has achieved key regulatory approvals in two international markets. In Azerbaijan, the company's manufacturing facility was inspected by the Ministry of Health from April 13-17, 2026, and GMP approval is expected within 1-2 months, which combined with existing EAEU approval will open the Azerbaijan and wider CIS markets. In the Philippines, the company received Certificates of Product Registration (CPR) for 2 brands — both being first generic approvals in the market — with more approvals expected over the next 6 months to support entry into Vietnam and Thailand. The company already holds approvals from PIC/S, ANVISA, INVIMA, and EAEU, and has triggered an EU GMP inspection.
These regulatory milestones expand Beta Drugs' geographic footprint into CIS and Southeast Asian markets, potentially boosting future export revenues once approvals convert to commercial sales.